🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsClinical Trials & ResearchSURMOUNT-MMO: tirzepatide for morbid obesity — trial update Page 3

SURMOUNT-MMO: tirzepatide for morbid obesity — trial update

SurmountFan_IN Thu, May 28, 2026 at 7:56 PM 11 replies 436 viewsPage 3 of 3
DanielChem_CHI
Senior Member
1,234
5,678
Mar 2024
Chicago, IL
May 31, 2026 at 6:51 PM#11
DebRD_ATL said:
Relative and absolute effects need reading together.

Agreed, and subgroup analyses deserve particular suspicion. With enough subgroups something is significant by chance, and pre-registered subgroups are a different animal from ones found afterwards.

Ask again with the specifics and you will get a better answer than this one.

20 20fiona_VT, denise_HTX, raj_cambridge and 17 others
Reply Quote Save Share Report
hannah_MT
New Member
23
89
Feb 2026
Bozeman, MT
Jun 2, 2026 at 2:45 PM#12
DadBodDave said:
Agreed on the mechanism, with the caveat that the head-to-head used semaglutide 1mg, not 2.4mg.

Genuinely useful, thank you. I had the facts and not the framework.

19 19MounjBrad, nick_newbie, DadBodDave and 16 others
Reply Quote Save Share Report
Dr.BariatricHTX
Senior Member
1,456
7,234
Feb 2024
Houston, TX
Jun 4, 2026 at 10:40 AM#13
DebRD_ATL said:
Relative and absolute effects need reading together.

Filing a mild objection. Mild because I might be wrong; an objection because nobody has addressed the case that does not fit. I would add the less popular caveat: these trial populations under-represented several groups, older adults and the highest BMI categories among them. The results probably generalise, and "probably" should be stated as an assumption rather than dropped.

18 18Dr.EM_Chicago, pete_RVA, CarlaRPh_TPA and 15 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
LabKate
Senior Member
2,678
11,234
Jan 2024
Oregon
Jun 6, 2026 at 6:36 AM#14

The figures, for anyone assembling their own picture. One practical note: write down what you did and when, before you need it. Reconstructing a timeline from memory three months later is how people end up unable to answer the one question that would have resolved it.

If somebody has the primary source to hand I would rather cite it than paraphrase it.

17 17emily_PDX, Dr.SleepRoch, laura_annarbor and 14 others
Reply Quote Save Share Report
Admin
Administrator
2,456
9,812
Oct 2023
Online
Jun 8, 2026 at 2:33 AM#15

Moderator note: the sourcing question belongs in the vendor section and has been split out. No action needed from anybody.

Last edited: Jun 8, 2026 at 6:33 AM
16 16PeptideSynthNJ, Dr.KarenChen, Dr.NateNeph and 13 others
Reply Quote Save Share Report

Similar Threads

FLOW trial: semaglutide renal outcomes — NEJM publication review14 replies
SELECT trial: semaglutide 2.4mg cardiovascular outcomes — 4yr data9 replies
TRIUMPH program (retatrutide) — Phase 3 trial design and endpoints13 replies
Orforglipron ATTAIN trials — oral non-peptide GLP-1 agonist8 replies
CagriSema (amylin + semaglutide) — REDEFINE Phase 3 results20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register